A citation-based method for searching scientific literature

Rohini Roy, Jarin Chun, Simon N Powell. Nat Rev Cancer 2011
Times Cited: 791







List of co-cited articles
647 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
3

BRCA mutation in ovarian cancer: testing, implications and treatment considerations.
Robert T Neff, Leigha Senter, Ritu Salani. Ther Adv Med Oncol 2017
54
5

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
733
3

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry Rosen, Harvey A Risch, Isabel Fan, Linda Bradley, Patricia A Shaw, Steven A Narod. Gynecol Oncol 2011
254
3

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Wataru Sakai, Elizabeth M Swisher, Beth Y Karlan, Mukesh K Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J Farrugia, Fergus J Couch,[...]. Nature 2008
692
3


Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
Xin Yang, Goska Leslie, Alicja Doroszuk, Sandra Schneider, Jamie Allen, Brennan Decker, Alison M Dunning, James Redman, James Scarth, Inga Plaskocinska,[...]. J Clin Oncol 2020
127
3

High grade serous ovarian carcinomas originate in the fallopian tube.
S Intidhar Labidi-Galy, Eniko Papp, Dorothy Hallberg, Noushin Niknafs, Vilmos Adleff, Michael Noe, Rohit Bhattacharya, Marian Novak, Siân Jones, Jillian Phallen,[...]. Nat Commun 2017
294
3

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
830
3

State-of-the-art strategies for targeting the DNA damage response in cancer.
Patrick G Pilié, Chad Tang, Gordon B Mills, Timothy A Yap. Nat Rev Clin Oncol 2019
385
3

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Luca Gianni. Nat Rev Clin Oncol 2016
3

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
673
3


BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.
S B Cantor, D W Bell, S Ganesan, E M Kass, R Drapkin, S Grossman, D C Wahrer, D C Sgroi, W S Lane, D A Haber,[...]. Cell 2001
498
3

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Andrea Desmond, Allison W Kurian, Michele Gabree, Meredith A Mills, Michael J Anderson, Yuya Kobayashi, Nora Horick, Shan Yang, Kristen M Shannon, Nadine Tung,[...]. JAMA Oncol 2015
217
3



Regulation of DNA double-strand break repair pathway choice.
Meena Shrivastav, Leyma P De Haro, Jac A Nickoloff. Cell Res 2008
858
3

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Mary B Daly, Tuya Pal, Michael P Berry, Saundra S Buys, Patricia Dickson, Susan M Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L Hutton,[...]. J Natl Compr Canc Netw 2021
131
3

BRCA1 gene: function and deficiency.
Miho Takaoka, Yoshio Miki. Int J Clin Oncol 2018
46
6


53BP1: a DSB escort.
Zachary Mirman, Titia de Lange. Genes Dev 2020
86
3

Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth. Nat Rev Cancer 2004
3

The DNA damage response: making it safe to play with knives.
Alberto Ciccia, Stephen J Elledge. Mol Cell 2010
3

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Saundra S Buys, John F Sandbach, Amanda Gammon, Gayle Patel, John Kidd, Krystal L Brown, Lavania Sharma, Jennifer Saam, Johnathan Lancaster, Mary B Daly. Cancer 2017
205
3

Genome-wide transcriptome profiling of homologous recombination DNA repair.
Guang Peng, Curtis Chun-Jen Lin, Wei Mo, Hui Dai, Yun-Yong Park, Soo Mi Kim, Yang Peng, Qianxing Mo, Stefan Siwko, Ruozhen Hu,[...]. Nat Commun 2014
138
3

Structure-Function Of The Tumor Suppressor BRCA1.
Serena L Clark, Ana M Rodriguez, Russell R Snyder, Gary D V Hankins, Darren Boehning. Comput Struct Biotechnol J 2012
86
3

The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
Martin Widschwendter, Adam N Rosenthal, Sue Philpott, Ivana Rizzuto, Lindsay Fraser, Jane Hayward, Maria P Intermaggio, Christopher K Edlund, Susan J Ramus, Simon A Gayther,[...]. Lancet Oncol 2013
79
3

Repair of strand breaks by homologous recombination.
Maria Jasin, Rodney Rothstein. Cold Spring Harb Perspect Biol 2013
493
3

Mechanisms of BRCA1 tumor suppression.
Daniel P Silver, David M Livingston. Cancer Discov 2012
87
3

Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls.
Yukihide Momozawa, Yusuke Iwasaki, Michael T Parsons, Yoichiro Kamatani, Atsushi Takahashi, Chieko Tamura, Toyomasa Katagiri, Teruhiko Yoshida, Seigo Nakamura, Kokichi Sugano,[...]. Nat Commun 2018
83
2

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman, Eitan Friedman, Shlomo Segev, Paul Renbaum, Rachel Beeri, Moran Gal, Julia Grinshpun-Cohen, Karen Djemal,[...]. Proc Natl Acad Sci U S A 2014
207
2

Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots".
Jennifer N Dines, Brian H Shirts, Thomas P Slavin, Tom Walsh, Mary-Claire King, Douglas M Fowler, Colin C Pritchard. Genet Med 2020
14
14

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Jessica S Brown, Brent O'Carrigan, Stephen P Jackson, Timothy A Yap. Cancer Discov 2017
307
2


Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-Based Cohort Analysis.
Yi-Jhih Huang, Tsai-Wang Huang, Fu-Huang Lin, Chi-Hsiang Chung, Chang-Huei Tsao, Wu-Chien Chien. J Thorac Oncol 2017
29
6

Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Suresh Hedau, Madhu Batra, Usha Rani Singh, Alok C Bharti, Amitabha Ray, Bhudev C Das. J Cancer Res Ther 2015
14
14

Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
Christine E Horak, Lajos Pusztai, Guan Xing, Ovidiu C Trifan, Cristina Saura, Ling-Ming Tseng, Stephen Chan, Rosanne Welcher, David Liu. Clin Cancer Res 2013
68
2

Targeting the replication stress response in cancer.
Josep V Forment, Mark J O'Connor. Pharmacol Ther 2018
82
2

An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication.
Tatiana N Moiseeva, Yandong Yin, Michael J Calderon, Chenao Qian, Sandra Schamus-Haynes, Norie Sugitani, Hatice U Osmanbeyoglu, Eli Rothenberg, Simon C Watkins, Christopher J Bakkenist. Proc Natl Acad Sci U S A 2019
48
4

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Stephanie A Yazinski, Valentine Comaills, Rémi Buisson, Marie-Michelle Genois, Hai Dang Nguyen, Chu Kwen Ho, Tanya Todorova Kwan, Robert Morris, Sam Lauffer, André Nussenzweig,[...]. Genes Dev 2017
198
2


Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Lin Mei, Junran Zhang, Kai He, Jingsong Zhang. J Hematol Oncol 2019
57
3

R-Loops as Cellular Regulators and Genomic Threats.
Madzia P Crossley, Michael Bocek, Karlene A Cimprich. Mol Cell 2019
244
2

Systematic identification of genomic markers of drug sensitivity in cancer cells.
Mathew J Garnett, Elena J Edelman, Sonja J Heidorn, Chris D Greenman, Anahita Dastur, King Wai Lau, Patricia Greninger, I Richard Thompson, Xi Luo, Jorge Soares,[...]. Nature 2012
2

DNA replication origin activation in space and time.
Michalis Fragkos, Olivier Ganier, Philippe Coulombe, Marcel Méchali. Nat Rev Mol Cell Biol 2015
254
2

Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells.
Ralph Zellweger, Damian Dalcher, Karun Mutreja, Matteo Berti, Jonas A Schmid, Raquel Herrador, Alessandro Vindigni, Massimo Lopes. J Cell Biol 2015
370
2

Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.
Rémi Buisson, Jessica L Boisvert, Cyril H Benes, Lee Zou. Mol Cell 2015
180
2

EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
Aparna Gorthi, July Carolina Romero, Eva Loranc, Lin Cao, Liesl A Lawrence, Elicia Goodale, Amanda Balboni Iniguez, Xavier Bernard, V Pragathi Masamsetti, Sydney Roston,[...]. Nature 2018
107
2

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
Philip M Reaper, Matthew R Griffiths, Joanna M Long, Jean-Damien Charrier, Somhairle Maccormick, Peter A Charlton, Julian M C Golec, John R Pollard. Nat Chem Biol 2011
406
2


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.